The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer’s Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The positive effects of galantamine on cognition and activities ofdaily living (ADL) in Alzheimer’s disease (AD) are thought to be mediated via improvementsin attention. The purpose of this study was to determine the effect of galantamine on attentionin AD patients using a computerized attention test and to elucidate the relationship between improvements in attention and change in cognition and ADL. Methods In this multicenter, open-label, prospective study, patients with mild to moderateAD received galantamine and then submitted to computerized attention tests, the Alzheimer’sDisease Assessment Scale-cognitive subscale, and instrumental ADL (IADL) at baseline, 4weeks, and 12 weeks. The differences in reaction time on computerized tests were explored relative to the changes in cognition and IADL. Results After 12 weeks of taking the trial medication there was a significant reduction frombaseline levels in the choice reaction time (baseline, 5,216±3,650 sec; 12 weeks, 4,139±2,920sec; p<0.01) and the simple reaction time (baseline, 1,089±782 sec; 12 weeks, 908±606 sec;p<0.01). Correlation analyses of changes in choice or simple reaction times relative to cognition and ADL measures yielded no significant associations. The improvement in attention observed at 4 weeks of galantamine treatment was not associated with any significant changes inoutcome measures at the end of trial. Conclusions This study found no significant association between the improvement in attention after treatment with galantamine and changes in cognition and ADL in patients with mildto moderate AD, despite the significant improvement in attention over the course of the treatment.
Abstract
Background and Purpose The positive effects of galantamine on cognition and activities ofdaily living (ADL) in Alzheimer’s disease (AD) are thought to be mediated via improvementsin attention. The purpose of this study was to determine the effect of galantamine on attentionin AD patients using a computerized attention test and to elucidate the relationship between improvements in attention and change in cognition and ADL. Methods In this multicenter, open-label, prospective study, patients with mild to moderateAD received galantamine and then submitted to computerized attention tests, the Alzheimer’sDisease Assessment Scale-cognitive subscale, and instrumental ADL (IADL) at baseline, 4weeks, and 12 weeks. The differences in reaction time on computerized tests were explored relative to the changes in cognition and IADL. Results After 12 weeks of taking the trial medication there was a significant reduction frombaseline levels in the choice reaction time (baseline, 5,216±3,650 sec; 12 weeks, 4,139±2,920sec; p<0.01) and the simple reaction time (baseline, 1,089±782 sec; 12 weeks, 908±606 sec;p<0.01). Correlation analyses of changes in choice or simple reaction times relative to cognition and ADL measures yielded no significant associations. The improvement in attention observed at 4 weeks of galantamine treatment was not associated with any significant changes inoutcome measures at the end of trial. Conclusions This study found no significant association between the improvement in attention after treatment with galantamine and changes in cognition and ADL in patients with mildto moderate AD, despite the significant improvement in attention over the course of the treatment.
참고문헌 (20)
- Wilkinson DG, "Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy", Drugs Aging, 21, pp.453~478 (2004)
- Whitehead A, "Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials", Int J Geriatr Psychiatry, 19, pp.624~633 (2004)
- Suh GH, "A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population", Clin Ther, 26, pp.1608~1618 (2004)
- Farlow M, "A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease", Eur Neurol, 44, pp.236~241 (2000)
- Brousseau G, "Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer’s disease subtypes: an alternate hypothesis to global cognitive enhancement", Exp Clin Psychopharmacol, 15, pp.546~554 (2007)
- Kadir A, "PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease", Psychopharmacology, 188, pp.509~520 (2006)
- Daiello LA, "Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease", J Clin Psychopharmacol, 30, pp.245~251 (2010)
- Belleville S, "Working memory and control of attention in persons with Alzheimer’s disease and mild cognitive impairment", Neuropsychology, 21, pp.458~469 (2007)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Wilcock GK, "Efficacy and safety of galan-tamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial", BMJ, 321, pp.1445~1449 (2000), Galantamine International-1 Study Group
- Tariot PN, "A 5-month, randomized, placebo-controlled trial of galantamine in AD", Neurology, 54, pp.2269~2276 (2000), The Galantamine USA-10 Study Group
- Wilkinson D, "Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease", Int J Geriatr Psychiatry, 16, pp.852~857 (2001)
- Feldman H, "Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden", J Am Geriatr Soc, 51, pp.737~744 (2003)
- Reisberg B, "Memantine in moderate-to-severe Alzheimer’s disease", N Engl J Med, 348, pp.1333~1341 (2003)
- Galvin JE, "Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil", Alzheimer Dis Assoc Disord, 22, pp.30~38 (2008)
- Gorus E, "The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients", J Clin Psychopharmacol, 27, pp.182~187 (2007)
- Jones GM, "Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease", Psychopharmacology, 108, pp.485~494 (1992)
- Albuquerque EX, "Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity", J Recept Signal Transduct Res, 17, pp.243~266 (1997)
- Lawrence AD, "Alzheimer disease, attention, and the cholinergic system", Alzheimer Dis Assoc Disord, 9(2), pp.43~49 (1995)
- Perry RJ, "Attention and executive deficits in Alzheimer’s disease. A critical review", Brain, 122(3), pp.383~404 (1999)